134 related articles for article (PubMed ID: 17323177)
1. Preventative ibandronate treatment has the most beneficial effect on the microstructure of bone in experimental tumor osteolysis.
Kurth AA; Kim SZ; Shea M; Bauss F; Hayes WC; Müller R
J Bone Miner Metab; 2007; 25(2):86-92. PubMed ID: 17323177
[TBL] [Abstract][Full Text] [Related]
2. Impact of oral ibandronate 150 mg once monthly on bone structure and density in post-menopausal osteoporosis or osteopenia derived from in vivo μCT.
Bock O; Börst H; Beller G; Armbrecht G; Degner C; Martus P; Roth HJ; Felsenberg D
Bone; 2012 Jan; 50(1):317-24. PubMed ID: 22067902
[TBL] [Abstract][Full Text] [Related]
3. Ibandronate treatment decreases the effects of tumor-associated lesions on bone density and strength in the rat.
Kurth AA; Kim SZ; Sedlmeyer I; Bauss F; Shea M
Bone; 2002 Jan; 30(1):300-6. PubMed ID: 11792601
[TBL] [Abstract][Full Text] [Related]
4. The effect of an osteolytic tumor on the three-dimensional trabecular bone morphology in an animal model.
Kurth AA; Müller R
Skeletal Radiol; 2001 Feb; 30(2):94-8. PubMed ID: 11310206
[TBL] [Abstract][Full Text] [Related]
5. Effects of treatment with ibandronate on bone mass, architecture, biomechanical properties, and bone concentration of ibandronate in ovariectomized aged rats.
Bauss F; Lalla S; Endele R; Hothorn LA
J Rheumatol; 2002 Oct; 29(10):2200-8. PubMed ID: 12375334
[TBL] [Abstract][Full Text] [Related]
6. [Anti-osteolytic therapy preserves trabecular structure and mechanical properties of bone in tumor osteolysis].
Kurth AA; Kim SZ; Bauss F; Müller R; Hovy L
Z Orthop Ihre Grenzgeb; 2000; 138(2):146-51. PubMed ID: 10820881
[TBL] [Abstract][Full Text] [Related]
7. Regional distribution of spine and hip QCT BMD responses after one year of once-monthly ibandronate in postmenopausal osteoporosis.
Engelke K; Fuerst T; Dasic G; Davies RY; Genant HK
Bone; 2010 Jun; 46(6):1626-32. PubMed ID: 20226286
[TBL] [Abstract][Full Text] [Related]
8. Local administration of ibandronate and bone morphogenetic protein-2 after ischemic osteonecrosis of the immature femoral head: a combined therapy that stimulates bone formation and decreases femoral head deformity.
Vandermeer JS; Kamiya N; Aya-ay J; Garces A; Browne R; Kim HK
J Bone Joint Surg Am; 2011 May; 93(10):905-13. PubMed ID: 21593365
[TBL] [Abstract][Full Text] [Related]
9. Oral ibandronate preserves trabecular microarchitecture: micro-computed tomography findings from the oral iBandronate Osteoporosis vertebral fracture trial in North America and Europe study.
Recker RR; Ste-Marie LG; Langdahl B; Masanauskaite D; Ethgen D; Delmas PD
J Clin Densitom; 2009; 12(1):71-6. PubMed ID: 19084450
[TBL] [Abstract][Full Text] [Related]
10. The bisphosphonate ibandronate improves implant integration in osteopenic ovariectomized rats.
Kurth AH; Eberhardt C; Müller S; Steinacker M; Schwarz M; Bauss F
Bone; 2005 Aug; 37(2):204-10. PubMed ID: 15936997
[TBL] [Abstract][Full Text] [Related]
11. Association between histomorphometry and biochemical markers of bone turnover in a longitudinal rat model of parathyroid hormone-related peptide (PTHrP)-mediated tumor osteolysis.
Juraschek M; Seibel MJ; Woitge HW; Krempien B; Bauss F
Bone; 2000 May; 26(5):475-83. PubMed ID: 10773587
[TBL] [Abstract][Full Text] [Related]
12. Intermittent ibandronate preserves bone quality and bone strength in the lumbar spine after 16 months of treatment in the ovariectomized cynomolgus monkey.
Müller R; Hannan M; Smith SY; Bauss F
J Bone Miner Res; 2004 Nov; 19(11):1787-96. PubMed ID: 15476578
[TBL] [Abstract][Full Text] [Related]
13. Treatment with ibandronate preserves bone in experimental tumour-induced bone loss.
Kurth AH; Kim SZ; Sedlmeyer I; Hovy L; Bauss F
J Bone Joint Surg Br; 2000 Jan; 82(1):126-30. PubMed ID: 10697328
[TBL] [Abstract][Full Text] [Related]
14. Unwrapping microcomputed tomographic images for measuring cortical osteolytic lesions in the 5T2 murine model of myeloma treated by bisphosphonate.
N'Diaye M; Libouban H; Aguado E; Bouvard B; Audran M; Chappard D
Micron; 2015 Jan; 68():107-114. PubMed ID: 25464148
[TBL] [Abstract][Full Text] [Related]
15. Effects of ibandronate on bone quality: preclinical studies.
Bauss F; Dempster DW
Bone; 2007 Feb; 40(2):265-73. PubMed ID: 16996333
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of monthly oral ibandronate in the prevention of postmenopausal bone loss.
McClung MR; Bolognese MA; Sedarati F; Recker RR; Miller PD
Bone; 2009 Mar; 44(3):418-22. PubMed ID: 18950736
[TBL] [Abstract][Full Text] [Related]
17. Micro-CT imaging analysis for the effects of ibandronate and eldecalcitol on secondary osteoporosis and arthritis in adjuvant-induced arthritis rats.
Ono Y; Miyakoshi N; Kasukawa Y; Imai Y; Nagasawa H; Tsuchie H; Akagawa M; Nagahata I; Yuasa Y; Sato C; Kawatani M; Shimada Y
Biomed Res; 2019; 40(5):197-205. PubMed ID: 31597905
[TBL] [Abstract][Full Text] [Related]
18. Short-term administration of the bisphosphonate ibandronate increases bone volume and prevents hyperparathyroid bone changes in mild experimental renal failure.
Geng Z; Monier-Faugere MC; Bauss F; Malluche HH
Clin Nephrol; 2000 Jul; 54(1):45-53. PubMed ID: 10939756
[TBL] [Abstract][Full Text] [Related]
19. Ibandronate for prevention of femoral head deformity after ischemic necrosis of the capital femoral epiphysis in immature pigs.
Kim HK; Randall TS; Bian H; Jenkins J; Garces A; Bauss F
J Bone Joint Surg Am; 2005 Mar; 87(3):550-7. PubMed ID: 15741621
[TBL] [Abstract][Full Text] [Related]
20. Protective actions of green tea polyphenols and alfacalcidol on bone microstructure in female rats with chronic inflammation.
Shen CL; Yeh JK; Samathanam C; Cao JJ; Stoecker BJ; Dagda RY; Chyu MC; Wang JS
J Nutr Biochem; 2011 Jul; 22(7):673-80. PubMed ID: 21036589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
